3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
235
Lymphoma
30
Hematologic Neoplasms
21
Recurrence
18
Neoplasms
14
Neoplasms, Plasma Cell
13
Lymphoma, Non-Hodgkin
13
Immunoglobulin Light-chain Amyloidosis
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Leukemia, Myeloid, Acute
10
Lymphoma, Mantle-Cell
9
Smoldering Multiple Myeloma
8
Prostatic Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Myelodysplastic Syndromes
8
Lymphoma, Large B-Cell, Diffuse
8
Hodgkin Disease
8
Ovarian Neoplasms
6
Lung Neoplasms
6
Leukemia, Plasma Cell
6
Breast Neoplasms
6
Waldenstrom Macroglobulinemia
5
Melanoma
5
Lymphoma, Follicular
5
Monoclonal Gammopathy of Undetermined Significance
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Amyloid Neuropathies, Familial
×
Plasma cell
×
30 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled